Pregabalin and Topiramate Reduced Anxiety and Motor Symptoms During Cannabis Withdrawal in Mice

Both pregabalin and topiramate reduced anxiety-like behavior and motor symptoms during spontaneous cannabinoid withdrawal in mice, while also reversing withdrawal-related gene expression changes in the brain.

Aracil-Fernández, Auxiliadora et al.·Addiction biology·2013·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-00644Animal StudyPreliminary Evidence2013RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Mice made tolerant to the synthetic cannabinoid CP-55,940 showed increased motor activity, rearing, and anxiety-like behavior on days 1 and 3 after cessation. Both pregabalin (40 mg/kg twice daily) and topiramate (50 mg/kg twice daily) blocked the motor signs and significantly reduced anxiety.

At the molecular level, cannabinoid withdrawal decreased tyrosine hydroxylase expression in the reward center and mu-opioid receptor expression in the nucleus accumbens, while increasing CB1 receptor expression. Both drugs reversed the tyrosine hydroxylase and CB1 changes but did not affect the opioid receptor changes.

Key Numbers

CP-55,940: 0.5 mg/kg twice daily for 7 days. Pregabalin: 40 mg/kg twice daily. Topiramate: 50 mg/kg twice daily. Both blocked motor signs and reduced anxiety on days 1 and 3. Both reversed TH decrease and CB1 increase in brain. Neither affected mu-opioid receptor changes.

How They Did This

Mice received CP-55,940 (0.5 mg/kg twice daily for 7 days) to induce tolerance. Spontaneous withdrawal was assessed on days 1 and 3 by measuring motor activity, somatic signs, and anxiety-like behavior. Pregabalin or topiramate was administered during days 1-3. Gene expression was measured by qRT-PCR in VTA and nucleus accumbens.

Why This Research Matters

Cannabis withdrawal, while not life-threatening, includes anxiety, irritability, and sleep disturbance that often drive relapse. Identifying existing medications that can manage these symptoms could improve quit success rates. Both pregabalin and topiramate are already approved for other conditions.

The Bigger Picture

Finding that existing, approved medications can manage cannabinoid withdrawal symptoms accelerates the path to clinical application. The gene expression findings provide mechanistic insight into how these drugs work, potentially guiding development of even more targeted treatments.

What This Study Doesn't Tell Us

Animal study using a synthetic cannabinoid (CP-55,940) rather than THC, which may produce different withdrawal profiles. Mouse doses do not directly translate to human doses. Spontaneous withdrawal from 7 days of treatment may not model the withdrawal experienced by chronic human users. The anxiety measures are behavioral proxies, not direct measures of subjective experience.

Questions This Raises

  • ?Would pregabalin or topiramate help human cannabis users manage withdrawal?
  • ?Are the effective doses safe and tolerable in humans?
  • ?Would these medications improve quit rates in clinical trials?

Trust & Context

Key Stat:
Both drugs blocked motor symptoms and reduced anxiety during withdrawal
Evidence Grade:
Animal study with behavioral and molecular outcomes; preliminary evidence for repurposing existing medications.
Study Age:
Published in 2013. Clinical trials of these and related medications for cannabis withdrawal have continued.
Original Title:
Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice.
Published In:
Addiction biology, 18(2), 252-62 (2013)
Database ID:
RTHC-00644

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What is pregabalin and topiramate?

Pregabalin (Lyrica) is approved for nerve pain, fibromyalgia, and epilepsy. Topiramate (Topamax) is approved for epilepsy and migraine prevention. This study found both could reduce anxiety and motor symptoms during cannabis withdrawal in mice, suggesting potential repurposing for cannabis cessation support.

Does cannabis withdrawal cause anxiety?

Yes, in this mouse model, stopping cannabinoid administration produced significant anxiety-like behavior that persisted through day 3 of withdrawal. In humans, anxiety is one of the most commonly reported cannabis withdrawal symptoms and a frequent reason for relapse.

Read More on RethinkTHC

Cite This Study

RTHC-00644·https://rethinkthc.com/research/RTHC-00644

APA

Aracil-Fernández, Auxiliadora; Almela, Pilar; Manzanares, Jorge. (2013). Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice.. Addiction biology, 18(2), 252-62. https://doi.org/10.1111/j.1369-1600.2011.00406.x

MLA

Aracil-Fernández, Auxiliadora, et al. "Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice.." Addiction biology, 2013. https://doi.org/10.1111/j.1369-1600.2011.00406.x

RethinkTHC

RethinkTHC Research Database. "Pregabalin and topiramate regulate behavioural and brain gen..." RTHC-00644. Retrieved from https://rethinkthc.com/research/aracil-fernandez-2013-pregabalin-and-topiramate-regulate

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.